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ABSTRACT 
Objective: Antiepileptic drugs (AED) are administered either singly or in combination with other drugs. Their pharmacokinetics is influenced by 
drug-drug interaction & inter-individual variations. Lamotrigine (LTG) is a second order AED with similar constraints.  
Hence studying the relationship between lamotrigine dosage and plasma concentration was undertaken to offer assistance in therapeutic regimen. 
Methods: Pre-dose blood samples for lamotrigine estimation were obtained from 267 patients (138adults & 127children) including 2 pregnant 
women. Lamotrigine estimation was done by high performance liquid chromatography.  
Results: In our study more children (73%) than adults (34%) were on adjunctive therapy with inhibitors (valproic acid) or inducers (phenytoin, 
carbamazepine, oxcarbamazepine). Irrespective of co-therapy lamotrigine level within therapeutic range with an optimal seizure control was 
obtained only in 76% of children and 65% adults. In case of polytherapy with valproic acid, when lamotrigine dose was maintained similar or lower 
than monotherapy, lamotrigine levels were 105% and 65% higher in adults and children respectively. Increased volume as observed in pregnancy 
had a remarkable influence on lamotrigine level. An increase in drug dose with an increase in gestation was required in both pregnant women to 
maintain the plasma level.  
Conclusion: Inter-individual variations, co-medications and clinical conditions like pregnancy influence plasma lamotrigine level. Thus, drug 
monitoring is essential to obtain therapeutic efficacy for individual dose optimization.  
Keywords: Lamotrigine, Adjunctive therapy, Inter-individual variation, Drug monitoring. 
 
INTRODUCTION 
Lamotrigine (LTG) is a broad spectrum second line anticonvulsant 
belonging to phenyltriazine class. It was approved by Food and Drug 
Administration (FDA) for both montherapy and adjunctive 
antiepileptic therapy for partial seizures in adults & pediatric 
patients older than 2 years [1, 2]. It is also approved for adjunctive 
use in Lennox-Gastaut syndrome and bipolar disorders. LTG has 
been experimented in virtually all types of epilepsy including 
absence and reflex seizures, status epilepticus and especially in 
epilepsy refractory to other medications [1, 3]. 
Approximately 55% of LTG in plasma is bound to proteins and has a 
volume distribution of 1.2 L/kg [4]. It exerts its antiepileptic effect 
by inhibiting the activation of voltage-sensitive sodium channels 
thereby stabilizing the neuronal membranes [5].  
This further modulates the presynaptic release of an excitatory 
neurotransmitters (e.g.: glutamate, aspartate). It is also known to 
modulate the calcium and potassium currents [4]. LTG is rapidly 
absorbed from the gastro-intestinal tract and is only 50–60% bound 
to serum proteins [2]. It has a bioavailability of approximately 100% 
[6]. It is metabolized predominantly by glucuronidation pathway 
with UDP glucuronyl transferase to its inactive 2-N and 5-N 
glucoronide conjugates [3]. 
In healthy volunteers and patients receiving monotherapy, the mean 
half-life of LTG ranges from 23-37 hrs [7]. Its clearance is influenced 
by concomitant administration of other drugs. Enzyme inducing 
antiepileptic agents such as phenytoin or carbamazepine reduce its 
half-life to 8-20 hrs resulting in low drug level [8] while valproic acid 
(VPA) down-regulates the metabolism of lamotrigine, thereby 
extending its half-life to 60 hrs and necessitating a reduced dose [3]. 
Autoinduction is also a common phenomenon in LTG therapy. 
Autoinduction is usually complete within two weeks; with ~20% 
reduction in steady state serum/plasma concentrations if the dose is 
not changed [2]. The levels are influenced by other drugs like 
estrogens, progestin and HIV protease inhibitors [8]. In addition, its 
clearance is significantly reduced in case of hepatic and renal 
impairment. Also there is a fairly clear concentration threshold 
above which toxic side effects such as headache, nausea, dizziness, 
diplopia, ataxia, tremor, somnolence, blurred vision, increased 
seizure frequency and skin rash occur. In rare cases, complexes such 
as Steven Johnson Syndrome, toxic epidermal necrolysis etc also 
occur [9]. Besides inter-individual variation and drug-drug 
interactions, LTG levels also vary in pregnancy. Around 25% of 
epileptic patients are women in child bearing age [10].Though LTG 
is a safe drug in pregnancy with minimal fetal malformations, its 
clearance varies substantially with gestation[8,10]. All these factors 
lead to a large inter-individual variability in dose requirement 
further complicating the clinical use of LTG [2]. The role of 
therapeutic drug monitoring (TDM) for lamotrigine has been well 
emphasized in literature [6, 8, 11, 12].TDM for LTG is performed by 
analytical techniques like high-performance liquid chromatography 
(HPLC) [2, 8] and requires an expertise to process and report the 
test results. This limits availability of the testing facility to few 
referral centers. To the best of our knowledge, estimation of LTG is 
not available in India. The diagnostic centers were outsourcing the 
estimation to foreign laboratories. Hence we optimized this service 
in our laboratory using HPLC system. This clinical service has helped 
to achieve therapeutic goals for maximum efficacy. In the present 
article, we report a retrospective evaluation of LTG levels estimated 
in our laboratory over a period of two years. 
MATERIALS AND METHODS 
The study was approved by the Institutional Research Committee. A 
pre dose EDTA blood sample along with demographic details, drug 
dose, time from last dose, duration of therapy, co-medications and 
other relevant information including seizure frequency was 
obtained in the predefined clinical proforma. Pre-dose (trough) 
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blood samples were collected from all the subjects. The data was 
sorted as per the drug levels, dosage, concomitant therapy and 
clinical condition. 
Lamotrigine Estimation 
The plasma was separated immediately and was stored at -200
Group III: Receiving LTG & inducers such as Phenytoin, carbamazepine 
or oxcarbamazepine 
C 
until analysis. A rapid and sensitive HPLC method was used. The 
estimation was done on Waters 1525 multisolvent delivery system 
pump and Waters 2487 variable wavelength UV–visible detector 
using a commercially available kit, ClinRep from RECIPE (Germany). 
After protein precipitation and dilution with internal standard, 
supernatant was injected using an auto sampler [13]. An internal 
standard recovery of 80-120 % was aimed to ensure quality of test 
results. Two level controls were processed in every batch for accuracy 
and calibrator was injected both at the start and end of the batch to 
assess precision and ensure minimal carry over during the analysis. 
Data Analysis 
The subjects were grouped based on age, gender and concomitant 
therapy. Based on concomitant therapy, the patient population was 
classified into three groups 
Group I: Receiving Lamotrigine (LTG) monotherapy 
Group II: Receiving LTG & inhibitor valproic acid (VPA) 
Statistical Analysis 
All the study variables are given as mean ± standard deviation 
(SD).The statistical evaluation to assess the correlation of LTG dose, 
age, gender, co-medication etc. with LTG plasma level was 
performed using multivariate linear regression analysis. The 
regression analysis was performed using Epi Info software. (Epi 
InfoTM
Results 
 3.5.3)  
Patients Demographics 
Over the period of 2years we had received 265 samples which 
included 127children and 138adults. In addition, there were 
requests for 2 pregnant women for whom drug levels were 
performed in all trimesters. Amongst the subjects, more adults were 
on monotherapy as compared to children and in case of polytherapy, 
valproic acid (VPA) was the preferred drug in both the groups. 
Unlike children the adult group comprised of more females as 
compared to the males (Table 1). No gender bias was noted in the 
drug level and hence the data is presented as a mean of both in each 
group (Table 1). Concentration/dose (C/D) ratio was also calculated 
to assess variation due to age and concomitant therapy. It is evident 
from Table 1 that adjunctive therapy with VPA increases C/D 
amongst children as well as adults. 
  
Table 1: Lamotrigine Drug Level vs. Dose 
 CHILDREN (n=127) 
Age(years) = 8±4 
ADULT (n=138) 













Total number of patients 34 85 8 91 34 13 
Gender 
(male/female) 
18/16 49/36 6/2 23/68 8/26 8/13 
Lamotrigine dose (mg/kg/day) 4.5±2.6 5.0±2.9 6.9±1.0 5.5±2.0 3.9±1.9 4.3±1.7 
Lamotrigine level 
( mg /l) 
5.6±2.3 9.2±3.1 4.9±2.0 5.5±1.9 11.3±3.0 2.8±2.7 
C/ D ratio 
(mg/l/mg/kg/day) 
1.4±0.9 2.5±1.5 1.5±0.9 1.4±1.0 3.4±0.5 1.4±0.7 
Lamotrigine dose/kg body weight when compared with the LTG concentrations (Figure 1) suggest that amongst children on similar LTG dose, the 
levels showed a 65% increase in case of co-medication with VPA while amongst adults, 105% increase in concentration was obtained even when 
LTG dose was reduced by 29%. 
 
Table 2: LTG Levels in Our Study Population 

















Sub -Therapeutic 18(14%) 2.1±1.2 1.3±0.7 37(27%)  2.5±1.2 1.5±0.6 
Therapeutic 96(76%) 5.0±3.8 7.4±3.03 90(65%)  4.4±2.6 7.30±3.41 
Toxic 13(10%) 5.5±2.4 17.9±3.0 11(8%) 5.7±3.0 19.6±2.2 
 
The inducers reduced the drug level notably amongst adults while in 
children a drug dose as high as 6.9mg/kg/day was required to attain 
therapeutic level i.e. 4.9mg/l as compared to children on 
monotherapy. 
Therapeutic Range and LTG Levels 
A therapeutic range of 3-14 mg/l was used in our laboratory based 
on a study done by Morris et al [8]. The reference range has been 
widely accepted and applied in management of patients with 
epilepsy [2-3, 8]. Approximately 76% of the children (n=96) and 
65% of adults (n=90) had their LTG level within therapeutic range. 
 Irrespective of mono/polytherapy the LTG dose was between 100-
400mg (209±160mg or 4.18±1.8 mg/kg/day).  
LTG level in sub-therapeutic range with poor seizure control was 
noted in 14% children (n=18) and 27% adults (n=37). 
 
Key: Bar Graph: Lamotrigine dose (mg/kg/day), Line Graph: 
Lamotrigine level (mg /l) 
Fig. 1: It shows correlation between lamotrigine concentration 
& dose 
Tester et al. 




While LTG levels above therapeutic range were obtained in 10% 
children (n=13) and 8% adults (n=11) (Table 2).Increased drug 
levels were associated with toxic effects like rash, diplopia and 
dizziness in these patients. 
On summarizing, around 70% of our patients showed a good seizure 
control and were within therapeutic range while 30% (n=79) had 
sub-therapeutic or toxic levels. An appropriate dose modification in 
lamotrigine as well as adjunctive drugs was warranted in these 30% 
patients to obtain seizure control. 
Lamotrigine in Pregnancy 
In both our patients an increase in LTG clearance during pregnancy 
was observed. In the first patient, the drug dose was increased from 
75mg OD to 75mg BD and later to 100mg BD during the pregnancy. 
However, irrespective of the dose, her trough level ranged from 2–
2.8mg/l while the peak level (2–3 hrs.after dose) ranged from 2.7–
4mg/l throughout the pregnancy. The drug level in our second 
patient who was maintained on 100mg BD dropped from 4.9mg/l to 
1.8mg/l in the first trimester. In the subsequent trimesters her dose 
was increased to 150mg BD and 200mg BD wherein her trough level 
was 3.8mg/l and 5.1mg/l respectively. 
Source of Variation 
Based on the values of partial regression coefficient and the p-value 
(Table 3) lamotrigine dosage was the most significant predictor of 
lamotrigine levels in adults, whereas it was moderately significant in 
children.
 
Table 3: Factors influencing lamotrigine concentration 




Factor  Partial Regression Coefficient () p-value Partial Regression Coefficient () p-value 
Lamotrigine dose 0.40 0.030 * 0.90 0.002 * 
VPA dose 0.04 0.007 0.01 0.006 
Age 0.29 0.038 0.02 0.127 
*Statistically significant 
 
The coefficient of determination (R2
DISCUSSION  
) for children & adults was 0.34 
& 0.83 respectively. Thus more than 80% of lamotrigine levels could 
be explained by factor such as lamotrigine dose in adults. While in 
children only 30% of LTG levels could be explained by LTG dose. 
The HPLC based assay is favored to be adapted in routine practice. 
The therapeutic range of LTG plasma concentration reported in the 
literature range from 3-14 mg/l (2-3, 8). Studies have proven that LTG 
tolerability is highly correlated with LTG serum concentration [14]. 
Around 30 %( n=79) of patients in our study (Table 2) had sub 
therapeutic (1.5±0.6mg/l) or toxic levels (18.6±2.7mg/l) with poor 
seizure control. In these patients drug monitoring and subsequent 
dose modifications helped to optimize clinical care. Above results 
accentuate the point that monitoring of drug level is warranted in 
patients with infrequent seizures wherein drug levels will guide 
dose adjustments to obtain coveted plasma level. Desired drug level for 
each patient is the concentration at which seizures are well controlled 
without adverse effects. This varies between patients according to 
epilepsy syndrome, seizure types and disease severity [15]. 
In our study group, LTG was mainly used to control refractory 
seizures wherein several dose alterations and drug combinations 
are prescribed. In such patients inter-individual variations, drug-
drug interaction etc. affect drug levels and monitoring would aid to 
achieve maximum clinical & therapeutic efficacy.  
We have also observed that there is a large inter-individual 
variability in LTG metabolism which is further affected by the co-
medications particularly inhibitors and inducers. VPA inhibits 
hepatic enzymes including LTG metabolizing enzyme UDP- 
glucorunyl transferase thereby decreasing LTG metabolism [16-17]. 
In our patients, children on same LTG dose showed a notably higher 
concentration when on co-medication with VPA (Figure 1). While 
the adults even though on a lower LTG dosage as compared to 
monotherapy had a higher LTG concentration due to VPA co-
therapy. Thus, our findings suggest that a marked lamotrigine 
dosage reduction may be required if VPA is to be introduced to a 
patients therapy. Alternatively, addition of valproate can be used to 
increase low plasma LTG concentrations without increase in LTG 
dosage. We also observed that in case of polytherapy with VPA, 
when lamotrigine dose was maintained similar or lower than 
monotherapy, lamotrigine levels were 105% higher in adults and 
only 65% higher in children (Figure 1). This could be because of 
varied lamotrigine clearance. Lamotrigine clearance is higher in 
children [11, 18] and moderately reduced in adults [18].  
The inducers (phenytoin, carbamazepine and oxcarbamazepine) 
also showed a remarkable reduction in levels in both the groups 
(children/adult). However a larger patient population would be 
required to obtain a profound correlation  
Multivariate linear regression analysis showed that lamotrigine dose 
influence lamotrigine concentration (Table 3).The study by Morris et 
al [6] reported that there is a linear relationship between LTG dose 
and LTG concentrations particularly under the influence of type of 
co-medication. Similar results are also reported in Japanese [19] & 
white populations [20]. Influence of age on LTG serum concentration 
was reported by Bartoli et al [11] and also by Armijo et al [21]. Our 
data did not show any significant association between age & LTG 
level. No gender bias in LTG level has been reported in literature [17, 
20] and the same has been observed in our study.  
LTG is a safe drug in pregnancy with minimal fetal anomalies [22]. 
However, its metabolism is significantly altered due to an increase in 
plasma volume leading to a decrease in LTG level [8]. In both our 
patients an increase in LTG dose with gestation was required to 
maintain plasma levels. The variation could be attributed to an 
increase in glomerular filtration rate (GFR), plasma volume and/or 
total body water and increased estrogen levels [10]. All these factors 
cause an accelerated glucuronidation leading to decrease in the drug 
level. Thus, drug monitoring ensures a seizure free pregnancy with 
minimal fetal toxicity. The volume reduction in postpartum period 
would also result in an increase in LTG concentration [23] and hence 
a simultaneous reduction in LTG dose would be required to reduce 
toxicity. In addition to the drug-drug interaction, polymorphisms in 
the UDP-glucuronosyl transferase 1-4(UGT1A4) and UDP-
glucuronosyl transferase-2B7 (UGT2B7) gene have been recently 
reported to influence LTG level [24]. 
CONCLUSION 
In conclusion it is evident that LTG metabolism has a wide inter-
individual variability and its clearance is influenced by co-
medications and pregnancy. Genotype variations reported may also 
influence drug level and hence monitoring of lamotrigine plasma 
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